Skip to content

Air-Q® SP Versus Air-Q® and I-gel: A Randomized Clinical Trial

Comparison of the Air-Q® Self-Pressurizing (SP) Intubating Laryngeal Airway With the Air-Q® Intubating Laryngeal Airway and I-gel for Airway Maintenance in Adults Under General Anesthesia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01592760
Enrollment
225
Registered
2012-05-07
Start date
2012-05-31
Completion date
2014-08-31
Last updated
2017-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngeal Masks

Keywords

air-Q SP, air-Q, i-gel, supraglottic airway device, laryngeal mask airway

Brief summary

The air-Q Self-Pressurizing Intubating Laryngeal Airway (aILA SP) is a modification of the air-Q Intubating Laryngeal Airway (aILA). Besides the i-gel, it is the only breathing tube that sits above the vocal cords that does not require inflation of a cuff with air. The purpose of this study is to compare the ability of the aILA-SP to maintain patency of a patient's airway during general anesthesia with that of the aILA and i-gel devices. As a measure of this ability, we hypothesized that the airway sealing pressures will be equal between the aILA-SP and aILA, but superior when comparing the aILA-SP to the i-gel (i-gel will be lower).

Detailed description

Laryngeal mask airways (LMAs) are a group of airway devices, alternatively referred to as supraglottic airways (SGAs), used in anesthesia that are positioned in the back of the throat (pharynx) above (supra) the glottis (windpipe opening) and the vocal cords. This is in contradistinction to a tracheal tube, which is an airway device that is placed through the vocal cords and extends to a position below the glottis (infraglottic) and resides in the trachea (windpipe). Since their first approval for use in the United States by the US Food and Drug Administration in the early 1990s, the application of SGAs has become more widespread. Initially, they were only used in anesthetized patients who were breathing on their own (i.e., spontaneously ventilating). This was, in large part, due to a relatively low airway seal pressure, the pressure with which the device seals against the throat, thereby, keeping the air pushed in by a breathing machine (ventilator) from getting into the stomach or leaking out around the device and out through the mouth - in either case, not going into the patient's lungs. The relatively low airway seal pressure (18 - 20 cmH2O) did not allow for the use of muscle relaxant (paralyzing) drugs and positive pressure ventilation. Successive generations of SGAs by a variety of manufacturers have overcome and continue to attempt to overcome limitations of earlier devices. In addition, accumulated clinical experience has made anesthesia providers more comfortable with their use. No SGA, however, is yet ideal, and incremental changes continue to appear to improve airway management and reduce airway morbidity (e.g., sore throat, jaw pain, etc.). The air-Q® Intubating Laryngeal Airway (aILA, Mercury Medical, Clearwater, FL) is a newer, commercially-available, SGA designed for use as a primary airway and as an intubation conduit. It is available in polyvinyl chloride (PVC)-based, single use and silicone-based, reusable models. Information on its safety and effectiveness from a randomized, controlled trial in adults, undergoing general anesthesia, compared to that of the silicone-based, reusable aILA versus the LMA-Proseal™ (pLMA, North America, San Diego, CA), the current gold standard for SGA airway seal pressure, is available. The air-Q® Self-Pressurizing (SP) Intubating Laryngeal Airway (aILA-SP, Mercury Medical, Clearwater, FL) is a commercially-available, modification of the silicone-based, reusable aILA. Its overall design is identical to the aILA, but incorporates a communication orifice between the air tube and cuff, which regulates airflow into and from the cuff during periods of positive pressure and spontaneous ventilation. As such, it incorporates a self-pressurizing cuff that does not require manual inflation. Such a cuff may be advantageous insofar as it dynamically adjusts its intra-cuff pressure and fit with the patient's pharyngeal and periglottic anatomy, which may lead to a reduction in airway morbidity, while still providing the high seal pressure afforded by the aILA design. Lastly, the i-gel (Intersurgical Inc., Liverpool, NY) is a commercially-available SGA that uses a thermoplastic elastomer to create a non-inflating, anatomically-conforming, periglottic cuff. Studies have shown it to be an easily inserted, effective airway device with a lower incidence of sore throat and neck complaints. With exception to the aILA-SP, it is the only other commercially-available SGA that does not require cuff inflation. To date, no reports are available on the clinical performance of the aILA-SP in relation to other SGAs. Thus, the primary purpose of this study is to compare the airway seal pressure (ASP) of the aILA-SP against the aILA and i-gel in adults undergoing general anesthesia. Airway seal pressure is the most common surrogate for ventilatory capacity used in SGA studies.

Interventions

DEVICEair-Q SP

air-Q SP placement for airway maintenance.

DEVICEair-Q

air-Q placement for airway maintenance.

DEVICEi-gel

i-gel placement for airway maintenance.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ≥ 18 years; * scheduled for an elective surgery or procedure; and * general anesthesia with placement of a SGA planned.

Exclusion criteria

* \< 18 years of age; * non-English speaking; * known or believed to be pregnant; * prisoner; * has impaired decision-making capacity; * has symptomatic untreated gastroesophageal reflux; * has had a prior esophagectomy; * has a known or suspected hiatal hernia; * has vomited within twenty-four hours of the surgery or procedure; * has known oral pathology making a proper SGA fit unlikely; or * has any condition for which the primary anesthesia care team deems intubation with a tracheal tube to be necessary.

Design outcomes

Primary

MeasureTime frameDescription
Airway Seal Pressure After Device PlacementMeasured within 5 minutes after device placement/study initiationAirway seal pressure is defined as the pressure in cmH2O at which the needle of a manometer attached to the anesthesia circuit reaches equilibration, associated with an audible air leak from the subject's oropharynx or gastric insufflation, limited to a maximum pressure of 40 cmH2O. It is measured with the subject's head and neck in neutral position, the expiratory valve on the anesthesia machine closed, and the fresh gas flow set to five liters per minute.

Secondary

MeasureTime frameDescription
Device Placement Success RateMeasured at the time of attempted study device placement immediately after the induction of general anesthesiaDevice placement success rate is defined as the proportion of devices successfully placed within three attempts at device placement.
Device Ease of InsertionReported by the device operator at the time successful device placement is recorded.Device ease of insertion is graded as either easy, slightly difficult, difficult, or impossible. The outcome measure is the proportion of successful study device placements recorded as easy versus slightly difficult versus difficult versus impossible.
Device Position in Relation to the Vocal CordsMeasured within 5 minutes of successful study device placementDevice position in relation to the vocal cords is assessed with a flexible fiberoptic camera and graded as follows: 1 = full view of the vocal cords, 2 = partial view of the vocal cords including the arytenoids, 3 = view of the epiglottis only, and 4 = other (device cuff, pharynx or other structures).
Device Use Time (Min)Measured between successful device placement and device removal for any reason, approximately 2 hoursDevice Use Time is the time recorded to the nearest minute of the period bounded by the time the device placement was determined to be adequate in the study subject to its withdrawal from the study subject.
Incidence of Gastric InsufflationMeasured within 5 minutes of device placement/study initiationGastric insufflation is present when audible air sounds are heard by stethoscope over the subject's epigastrium.
Device Placement TimeMeasured at device placement/study initiationDevice placement time is the time measured in seconds from when the study investigator picks up the airway device to confirmation of ventilation by the presence of an adequate end-tidal carbon dioxide tracing on the monitor.
Incidence of Oropharyngeal InjuryMeasured in the post-anesthesia care unit/recovery room within 15 minutes after device removalOropharyngeal injury is defined as a new lip, tongue, buccal, or pharyngeal abrasion or laceration or dental damage observed in the immediate recovery area after use of a study device.
Overall Clinical UsefulnessReported by the device operator at the time of device removalExcellent, good, fair, or inadequate. Scale defined by clinical measures and observations.
Oropharyngolaryngeal Morbidity at DischargeMeasured prior to discharge from phase II of the post-anesthesia care unit/recovery roomPerioperative oropharyngolaryngeal morbidity is assessed by the subject's response to standardized questions regarding oropharyngeal complaints.
Oropharyngolaryngeal Morbidity at 24 Hours Post-operativelyMeasured at 24 hours after device placement/study initiationPerioperative oropharyngolaryngeal morbidity is assessed by the subject's response to standardized questions regarding oropharyngeal complaints.
Incidence of Gastric AspirationMeasured between successful device placement and device removal for any reason.Gastric aspiration is present when gross gastric contents or bile is observed on or within the device or within the subject's oropharynx. The outcome is the proportion of study subjects in whom the outcome measure was observed.

Countries

United States

Participant flow

Participants by arm

ArmCount
Air-Q
air-Q Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA) air-Q SP: air-Q SP placement for airway maintenance.
90
Air-Q SP
air-Q Self-Pressurizing Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA) air-Q SP: air-Q SP placement for airway maintenance.
90
I-gel
i-gel, sizes 3, 4, and 5 (Intersurgical Inc., Liverpool, NY, USA) i-gel: i-gel placement for airway maintenance.
45
Total225

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
24-hour Follow-UpLost to Follow-up432

Baseline characteristics

CharacteristicI-gelAir-QAir-Q SPTotal
Age, Continuous40 years
STANDARD_DEVIATION 15
42 years
STANDARD_DEVIATION 14
45 years
STANDARD_DEVIATION 16
43 years
STANDARD_DEVIATION 15
Body Mass Index27 kg/m^2
STANDARD_DEVIATION 5
28 kg/m^2
STANDARD_DEVIATION 6
27 kg/m^2
STANDARD_DEVIATION 5
27 kg/m^2
STANDARD_DEVIATION 5
Device Size
3
2 participants0 participants0 participants2 participants
Device Size
3.5
0 participants32 participants42 participants74 participants
Device Size
4
35 participants0 participants0 participants35 participants
Device Size
4.5
0 participants58 participants48 participants106 participants
Device Size
5
7 participants0 participants0 participants7 participants
Device Size
Missing Data
1 participants0 participants0 participants1 participants
Mallampati Score
Class 1
17 participants41 participants33 participants91 participants
Mallampati Score
Class 2
25 participants43 participants42 participants110 participants
Mallampati Score
Class 3
2 participants4 participants11 participants17 participants
Mallampati Score
Class 4
1 participants0 participants1 participants2 participants
Mallampati Score
Missing Data
0 participants2 participants3 participants5 participants
Procedure Type
General Surgery
6 participants7 participants10 participants23 participants
Procedure Type
Orthopedic
35 participants72 participants70 participants177 participants
Procedure Type
Other
4 participants11 participants10 participants25 participants
Sex: Female, Male
Female
15 Participants32 Participants41 Participants88 Participants
Sex: Female, Male
Male
30 Participants58 Participants49 Participants137 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
1 / 901 / 901 / 45
serious
Total, serious adverse events
0 / 900 / 900 / 45

Outcome results

Primary

Airway Seal Pressure After Device Placement

Airway seal pressure is defined as the pressure in cmH2O at which the needle of a manometer attached to the anesthesia circuit reaches equilibration, associated with an audible air leak from the subject's oropharynx or gastric insufflation, limited to a maximum pressure of 40 cmH2O. It is measured with the subject's head and neck in neutral position, the expiratory valve on the anesthesia machine closed, and the fresh gas flow set to five liters per minute.

Time frame: Measured within 5 minutes after device placement/study initiation

ArmMeasureValue (MEAN)Dispersion
Air-QAirway Seal Pressure After Device Placement28 cmH2OStandard Deviation 6
Air-Q SPAirway Seal Pressure After Device Placement27 cmH2OStandard Deviation 8
I-gelAirway Seal Pressure After Device Placement24 cmH2OStandard Deviation 8
Secondary

Device Ease of Insertion

Device ease of insertion is graded as either easy, slightly difficult, difficult, or impossible. The outcome measure is the proportion of successful study device placements recorded as easy versus slightly difficult versus difficult versus impossible.

Time frame: Reported by the device operator at the time successful device placement is recorded.

ArmMeasureGroupValue (NUMBER)
Air-QDevice Ease of InsertionDifficult1 participants
Air-QDevice Ease of InsertionModerate Difficulty0 participants
Air-QDevice Ease of InsertionEasy73 participants
Air-QDevice Ease of InsertionSlight Difficulty16 participants
Air-QDevice Ease of InsertionMissing Data0 participants
Air-Q SPDevice Ease of InsertionModerate Difficulty0 participants
Air-Q SPDevice Ease of InsertionEasy77 participants
Air-Q SPDevice Ease of InsertionSlight Difficulty11 participants
Air-Q SPDevice Ease of InsertionDifficult1 participants
Air-Q SPDevice Ease of InsertionMissing Data1 participants
I-gelDevice Ease of InsertionMissing Data0 participants
I-gelDevice Ease of InsertionDifficult0 participants
I-gelDevice Ease of InsertionEasy38 participants
I-gelDevice Ease of InsertionModerate Difficulty0 participants
I-gelDevice Ease of InsertionSlight Difficulty7 participants
Secondary

Device Placement Success Rate

Device placement success rate is defined as the proportion of devices successfully placed within three attempts at device placement.

Time frame: Measured at the time of attempted study device placement immediately after the induction of general anesthesia

ArmMeasureGroupValue (NUMBER)
Air-QDevice Placement Success RateAttempt 31 participants
Air-QDevice Placement Success RateAttempt 26 participants
Air-QDevice Placement Success RateAttempt 183 participants
Air-Q SPDevice Placement Success RateAttempt 33 participants
Air-Q SPDevice Placement Success RateAttempt 23 participants
Air-Q SPDevice Placement Success RateAttempt 184 participants
I-gelDevice Placement Success RateAttempt 24 participants
I-gelDevice Placement Success RateAttempt 141 participants
I-gelDevice Placement Success RateAttempt 30 participants
Secondary

Device Placement Time

Device placement time is the time measured in seconds from when the study investigator picks up the airway device to confirmation of ventilation by the presence of an adequate end-tidal carbon dioxide tracing on the monitor.

Time frame: Measured at device placement/study initiation

ArmMeasureValue (MEAN)Dispersion
Air-QDevice Placement Time25 secondsStandard Deviation 11
Air-Q SPDevice Placement Time19 secondsStandard Deviation 9
I-gelDevice Placement Time21 secondsStandard Deviation 13
Secondary

Device Position in Relation to the Vocal Cords

Device position in relation to the vocal cords is assessed with a flexible fiberoptic camera and graded as follows: 1 = full view of the vocal cords, 2 = partial view of the vocal cords including the arytenoids, 3 = view of the epiglottis only, and 4 = other (device cuff, pharynx or other structures).

Time frame: Measured within 5 minutes of successful study device placement

ArmMeasureGroupValue (NUMBER)
Air-QDevice Position in Relation to the Vocal Cords162 participants
Air-QDevice Position in Relation to the Vocal Cords26 participants
Air-QDevice Position in Relation to the Vocal Cords314 participants
Air-QDevice Position in Relation to the Vocal Cords48 participants
Air-Q SPDevice Position in Relation to the Vocal Cords48 participants
Air-Q SPDevice Position in Relation to the Vocal Cords171 participants
Air-Q SPDevice Position in Relation to the Vocal Cords37 participants
Air-Q SPDevice Position in Relation to the Vocal Cords24 participants
I-gelDevice Position in Relation to the Vocal Cords43 participants
I-gelDevice Position in Relation to the Vocal Cords210 participants
I-gelDevice Position in Relation to the Vocal Cords34 participants
I-gelDevice Position in Relation to the Vocal Cords128 participants
Secondary

Device Use Time (Min)

Device Use Time is the time recorded to the nearest minute of the period bounded by the time the device placement was determined to be adequate in the study subject to its withdrawal from the study subject.

Time frame: Measured between successful device placement and device removal for any reason, approximately 2 hours

ArmMeasureValue (MEAN)Dispersion
Air-QDevice Use Time (Min)60 minutesStandard Deviation 34
Air-Q SPDevice Use Time (Min)65 minutesStandard Deviation 40
I-gelDevice Use Time (Min)70 minutesStandard Deviation 41
Secondary

Incidence of Gastric Aspiration

Gastric aspiration is present when gross gastric contents or bile is observed on or within the device or within the subject's oropharynx. The outcome is the proportion of study subjects in whom the outcome measure was observed.

Time frame: Measured between successful device placement and device removal for any reason.

ArmMeasureValue (NUMBER)
Air-QIncidence of Gastric Aspiration0 participants
Air-Q SPIncidence of Gastric Aspiration0 participants
I-gelIncidence of Gastric Aspiration0 participants
Secondary

Incidence of Gastric Insufflation

Gastric insufflation is present when audible air sounds are heard by stethoscope over the subject's epigastrium.

Time frame: Measured within 5 minutes of device placement/study initiation

ArmMeasureValue (NUMBER)
Air-QIncidence of Gastric Insufflation0 participants
Air-Q SPIncidence of Gastric Insufflation0 participants
I-gelIncidence of Gastric Insufflation0 participants
Secondary

Incidence of Oropharyngeal Injury

Oropharyngeal injury is defined as a new lip, tongue, buccal, or pharyngeal abrasion or laceration or dental damage observed in the immediate recovery area after use of a study device.

Time frame: Measured in the post-anesthesia care unit/recovery room within 15 minutes after device removal

ArmMeasureValue (NUMBER)
Air-QIncidence of Oropharyngeal Injury2 participants
Air-Q SPIncidence of Oropharyngeal Injury0 participants
I-gelIncidence of Oropharyngeal Injury1 participants
Secondary

Oropharyngolaryngeal Morbidity at 24 Hours Post-operatively

Perioperative oropharyngolaryngeal morbidity is assessed by the subject's response to standardized questions regarding oropharyngeal complaints.

Time frame: Measured at 24 hours after device placement/study initiation

ArmMeasureGroupValue (NUMBER)
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyFace Numbness0 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain on Speaking4 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain on Swallowing37 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyTongue Numbness1 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyTongue Swelling1 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelySore Throat42 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyEar Pain1 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain in Jaw3 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyHearing Change1 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyLip Numbness4 participants
Air-QOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain in Mouth6 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain in Mouth1 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelySore Throat50 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain on Swallowing37 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain in Jaw2 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain on Speaking2 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyTongue Swelling1 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyTongue Numbness0 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyFace Numbness0 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyLip Numbness2 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyEar Pain2 participants
Air-Q SPOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyHearing Change1 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyEar Pain1 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyFace Numbness0 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain in Jaw2 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelySore Throat15 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyLip Numbness1 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain on Swallowing7 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyTongue Swelling0 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain on Speaking2 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyHearing Change1 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyTongue Numbness3 participants
I-gelOropharyngolaryngeal Morbidity at 24 Hours Post-operativelyPain in Mouth1 participants
Secondary

Oropharyngolaryngeal Morbidity at Discharge

Perioperative oropharyngolaryngeal morbidity is assessed by the subject's response to standardized questions regarding oropharyngeal complaints.

Time frame: Measured prior to discharge from phase II of the post-anesthesia care unit/recovery room

ArmMeasureGroupValue (NUMBER)
Air-QOropharyngolaryngeal Morbidity at DischargeFace Numbness2 participants
Air-QOropharyngolaryngeal Morbidity at DischargePain on Speaking2 participants
Air-QOropharyngolaryngeal Morbidity at DischargeEar Pain2 participants
Air-QOropharyngolaryngeal Morbidity at DischargeTongue Numbness2 participants
Air-QOropharyngolaryngeal Morbidity at DischargeTongue Swelling2 participants
Air-QOropharyngolaryngeal Morbidity at DischargeSore Throat38 participants
Air-QOropharyngolaryngeal Morbidity at DischargePain in Jaw1 participants
Air-QOropharyngolaryngeal Morbidity at DischargePain on Swallowing29 participants
Air-QOropharyngolaryngeal Morbidity at DischargeLip Numbness4 participants
Air-QOropharyngolaryngeal Morbidity at DischargePain in Mouth2 participants
Air-QOropharyngolaryngeal Morbidity at DischargeHearing Change1 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargeTongue Swelling2 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargeSore Throat28 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargePain on Swallowing20 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargePain in Jaw0 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargePain in Mouth1 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargePain on Speaking3 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargeTongue Numbness2 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargeFace Numbness2 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargeLip Numbness3 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargeEar Pain4 participants
Air-Q SPOropharyngolaryngeal Morbidity at DischargeHearing Change0 participants
I-gelOropharyngolaryngeal Morbidity at DischargeEar Pain0 participants
I-gelOropharyngolaryngeal Morbidity at DischargeFace Numbness0 participants
I-gelOropharyngolaryngeal Morbidity at DischargePain in Jaw0 participants
I-gelOropharyngolaryngeal Morbidity at DischargeSore Throat7 participants
I-gelOropharyngolaryngeal Morbidity at DischargeLip Numbness1 participants
I-gelOropharyngolaryngeal Morbidity at DischargePain on Swallowing3 participants
I-gelOropharyngolaryngeal Morbidity at DischargeTongue Swelling1 participants
I-gelOropharyngolaryngeal Morbidity at DischargePain on Speaking0 participants
I-gelOropharyngolaryngeal Morbidity at DischargeHearing Change0 participants
I-gelOropharyngolaryngeal Morbidity at DischargeTongue Numbness1 participants
I-gelOropharyngolaryngeal Morbidity at DischargePain in Mouth0 participants
Secondary

Overall Clinical Usefulness

Excellent, good, fair, or inadequate. Scale defined by clinical measures and observations.

Time frame: Reported by the device operator at the time of device removal

ArmMeasureGroupValue (NUMBER)
Air-QOverall Clinical UsefulnessExcellent56 participants
Air-QOverall Clinical UsefulnessGood6 participants
Air-QOverall Clinical UsefulnessFair27 participants
Air-QOverall Clinical UsefulnessInadequate1 participants
Air-Q SPOverall Clinical UsefulnessInadequate0 participants
Air-Q SPOverall Clinical UsefulnessExcellent65 participants
Air-Q SPOverall Clinical UsefulnessFair21 participants
Air-Q SPOverall Clinical UsefulnessGood4 participants
I-gelOverall Clinical UsefulnessInadequate0 participants
I-gelOverall Clinical UsefulnessGood1 participants
I-gelOverall Clinical UsefulnessFair20 participants
I-gelOverall Clinical UsefulnessExcellent24 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026